{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:37:44Z","timestamp":1790933864556,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We present the case of a 74-year-old woman with behavioral variant frontotemporal dementia (bvFTD) linked to a pathogenic TANK-binding kinase 1 (TBK1) mutation (c.1349_1352del; p.Ile450Lysfs*15). During clinical workup, the patient underwent comprehensive biomarker analysis, including tau positron emission tomography (PET) and cerebrospinal fluid (CSF) seed amplification assay (SAA) for \u03b1-synuclein (\u03b1Syn). While CSF biomarkers for Alzheimer\u2019s disease were normal, the \u03b1Syn SAA was clearly positive, indicating misfolded \u03b1Syn aggregates. Tau PET revealed increased [<jats:sup>18<\/jats:sup>F]PI-2620 uptake in the basal ganglia. Genetic testing confirmed autosomal dominant TBK1-associated FTD. The patient\u2019s condition deteriorated over the following year, with rapid cognitive decline and the emergence of cortical signs. Post-mortem neuropathological analysis confirmed multiple proteinopathies: FTLD-TDP43 (subtype A), Lewy body disease (limbic type, Braak stage 5), argyrophilic grain disease (AGD), aging-related tau astrogliopathy (ARTAG), and primary age-related tauopathy (PART). This is the first reported TBK1-FTD case with in vivo detection of \u03b1Syn pathology via SAA and in vivo monitoring of tau pathology. The case expands the clinical and neuropathological spectrum of TBK1-associated FTD. Our findings support a broader interpretation of TBK1-associated neurodegeneration and highlight the importance of multimodal diagnostic approaches that integrate molecular, genetic, imaging, and neuropathological tools. This case also underscores the utility of \u03b1Syn SAA and tau PET in detecting co-pathologies that may otherwise remain clinically silent and illustrates the need for further studies exploring the molecular cross-talk between TBK1, tau, and \u03b1Syn pathologies.<\/jats:p>","DOI":"10.1186\/s40478-025-02081-1","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:14:05Z","timestamp":1753434845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Co-occurrence of multiple pathologies in a case of frontotemporal dementia with TBK1 mutation: first in vivo detection of alpha-synuclein and tau co-pathology"],"prefix":"10.1186","volume":"13","author":[{"given":"Alexander M.","family":"Bernhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Roeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wlasich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endy","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Longen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja V.","family":"Trossbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Gn\u00f6rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Herms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Giese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2081_CR1","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456. https:\/\/doi.org\/10.1093\/brain\/awr179","journal-title":"Brain"},{"key":"2081_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","volume":"149","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt AM, Longen S, Trossbach SV, Rossi M, Weckbecker D, Schmidt F et al (2025) A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for parkinson\u2019s disease. Acta Neuropathol 149:20. https:\/\/doi.org\/10.1007\/s00401-025-02853-y","journal-title":"Acta Neuropathol"},{"key":"2081_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nn.4000","volume":"18","author":"A Freischmidt","year":"2015","unstructured":"Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M\u00fcller K et al (2015) Haploinsufficiency of TBK1 causes Familial ALS and fronto-temporal dementia. Nat Neurosci 18:631\u2013636. https:\/\/doi.org\/10.1038\/nn.4000","journal-title":"Nat Neurosci"},{"key":"2081_CR4","doi-asserted-by":"publisher","first-page":"e2472","DOI":"10.1212\/WNL.0000000000007530","volume":"92","author":"SL Forrest","year":"2019","unstructured":"Forrest SL, Crockford DR, Sizemova A, McCann H, Shepherd CE, McGeachie AB et al (2019) Coexisting lewy body disease and clinical parkinsonism in frontotemporal Lobar degeneration. Neurology 92:e2472\u2013e2482. https:\/\/doi.org\/10.1212\/WNL.0000000000007530","journal-title":"Neurology"},{"key":"2081_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.10.003","volume":"6","author":"CAM Koriath","year":"2017","unstructured":"Koriath CAM, Bocchetta M, Brotherhood E, Woollacott IOC, Norsworthy P, Sim\u00f3n-S\u00e1nchez J et al (2017) The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: A longitudinal case report. Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit 6:75\u201381. https:\/\/doi.org\/10.1016\/j.dadm.2016.10.003","journal-title":"Alzheimer\u2019s Dementia: Diagnosis Assess Disease Monit"},{"key":"2081_CR6","doi-asserted-by":"publisher","unstructured":"Wilke C, Baets J, De Bleecker JL, Deconinck T, Biskup S, Hayer SN et al (2018) Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol Aging 62. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.10.010.:244.e9-244.e13","DOI":"10.1016\/j.neurobiolaging.2017.10.010"},{"key":"2081_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/humu.23161","volume":"38","author":"J van der Zee","year":"2017","unstructured":"van der Zee J, Gijselinck I, Van Mossevelde S, Perrone F, Dillen L, Heeman B et al (2017) TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum Mutat 38:297\u2013309. https:\/\/doi.org\/10.1002\/humu.23161","journal-title":"Hum Mutat"},{"key":"2081_CR8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.2967\/jnumed.123.265856","volume":"64","author":"G Blazhenets","year":"2023","unstructured":"Blazhenets G, Soleimani-Meigooni DN, Thomas W, Mundada N, Brendel M, Vento S et al (2023) [18F]PI-2620 binding patterns in patients with suspected alzheimer disease and frontotemporal Lobar degeneration. J Nucl Med 64:1980\u20131989. https:\/\/doi.org\/10.2967\/jnumed.123.265856","journal-title":"J Nucl Med"},{"key":"2081_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00401-024-02834-7","volume":"148","author":"L Slemann","year":"2024","unstructured":"Slemann L, Gn\u00f6rich J, Hummel S, Bartos LM, Klaus C, Kling A et al (2024) Neuronal and oligodendroglial, but not astroglial, Tau translates to in vivo Tau PET signals in individuals with primary Tauopathies. Acta Neuropathol 148:70. https:\/\/doi.org\/10.1007\/s00401-024-02834-7","journal-title":"Acta Neuropathol"},{"key":"2081_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2526","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M et al (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526","journal-title":"JAMA Neurol"},{"key":"2081_CR11","doi-asserted-by":"publisher","first-page":"100760","DOI":"10.1016\/j.jbc.2021.100760","volume":"296","author":"MH Abreha","year":"2021","unstructured":"Abreha MH, Ojelade S, Dammer EB, McEachin ZT, Duong DM, Gearing M et al (2021) TBK1 interacts with Tau and enhances neurodegeneration in Tauopathy. J Biol Chem 296:100760. https:\/\/doi.org\/10.1016\/j.jbc.2021.100760","journal-title":"J Biol Chem"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02081-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T09:14:06Z","timestamp":1753434846000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02081-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02081-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by our Institutional Review Board and patient gave consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Alexander Bernhardt is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Sebastian Longen reports full-time employment by AESKU.Diagnostics GmbH. In addition, he is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Svenja V. Trossbach reports full-time employment by MODAG GmbH. In addition, she is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. G\u00fcnter H\u00f6glinger is inventor of patents related to the treatment of synucleinopathies (United States Patent No.: US 10,918,628 B2, European Patent Patent No.: EP 17 787 904.6\u20131109 \/ 3 525 788). Armin Giese reports employment by and being a shareholder of MODAG GmbH. He is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Johannes Levin reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH. He is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. All other authors have no other competing interests to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}